However, enforcement data shows that an estimated 35-40% of compounding pharmacies continued producing tirzepatide formulations beyond the transition period, prompting the FDA's intensified enforcement actions in early 2026 [6]
If we consider that around one in eight Americans have already tried a GLP-1 drug, according to healthy policy organisation KFF, and that more than two in five adults in the US live with obesity, there is real opportunity for pharma companies to meet this demand
This prevents bacterial growth during the weeks between reconstitution and complete use
Vers des traitements non injectables (GLP-1 oral) Aujourdhui, la majorit des analogues du GLP-1 sont disponibles uniquement en injections
Conclusion: Is Semaglutide Right for You
Spotting or Breakthrough Bleeding Research Investigation of Women with Postmenopausal Uterine Bleeding: Clinical Practice Recommendations